Bispecific antibodies
-
TALVEY® and TECVAYLI® Combination Elicits Deep and Durable Responses in Heavily Pretreated Multiple Myeloma Patients with Extramedullary Disease
Johnson & Johnson announced promising results from the Phase 2 RedirecTT-1 study, which evaluated TALVEY (talquetamab) and TECVAYLI (teclistamab) in extramedullary multiple myeloma (EMD) patients. The combination therapy showed an impressive 78.9% overall response rate. These findings suggest a potential off-the-shelf treatment approach for a patient population with limited options and significant unmet needs.
